BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 31918398)

  • 21. Design, synthesis, biological evaluation and molecular modeling study of new thieno[2,3-d]pyrimidines with anti-proliferative activity on pancreatic cancer cell lines.
    Salem MSH; Abdel Aziz YM; Elgawish MS; Said MM; Abouzid KAM
    Bioorg Chem; 2020 Jan; 94():103472. PubMed ID: 31813475
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of pyrazolopyrimidine derivatives as potent BTK inhibitors with effective anticancer activity in MCL.
    Ran F; Liu Y; Liu M; Zhang D; Wang P; Dong J; Tang W; Zhao G
    Bioorg Chem; 2019 Aug; 89():102943. PubMed ID: 31031018
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel Pyrazolo[3,4-d]pyrimidines as Potential Cytotoxic Agents: Design, Synthesis, Molecular Docking and CDK2 Inhibition.
    Maher M; Kassab AE; Zaher AF; Mahmoud Z
    Anticancer Agents Med Chem; 2019; 19(11):1368-1381. PubMed ID: 31038080
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Highly selective Janus kinase 3 inhibitors based on a pyrrolo[2,3-d]pyrimidine scaffold: evaluation of WO2013085802.
    Norman P
    Expert Opin Ther Pat; 2014 Jan; 24(1):121-5. PubMed ID: 24147573
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structure-based design and synthesis of 1H-pyrazolo[3,4-d]pyrimidin-4-amino derivatives as Janus kinase 3 inhibitors.
    Yin Y; Chen CJ; Yu RN; Wang ZJ; Zhang TT; Zhang DY
    Bioorg Med Chem; 2018 Sep; 26(17):4774-4786. PubMed ID: 30139575
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design and synthesis of tricyclic JAK3 inhibitors with picomolar affinities as novel molecular probes.
    Gehringer M; Pfaffenrot E; Bauer S; Laufer SA
    ChemMedChem; 2014 Feb; 9(2):277-81. PubMed ID: 24403205
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis and biological evaluation of novel thieno[2,3-d]pyrimidine-based FLT3 inhibitors as anti-leukemic agents.
    Yang JS; Park CH; Lee C; Kim H; Oh C; Choi Y; Kang JS; Yun J; Jeong JH; Kim MH; Han G
    Eur J Med Chem; 2014 Oct; 85():399-407. PubMed ID: 25108079
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery and structure-activity relationship of novel diphenylthiazole derivatives as BTK inhibitor with potent activity against B cell lymphoma cell lines.
    Guo X; Yang D; Fan Z; Zhang N; Zhao B; Huang C; Wang F; Ma R; Meng M; Deng Y
    Eur J Med Chem; 2019 Sep; 178():767-781. PubMed ID: 31234030
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel 1H-pyrazolo[3,4-d]pyrimidin-6-amino derivatives as potent selective Janus kinase 3 (JAK3) inhibitors. Evaluation of their improved effect for the treatment of rheumatoid arthritis.
    Yin Y; Chen CJ; Yu RN; Shu L; Wang ZJ; Zhang TT; Zhang DY
    Bioorg Chem; 2020 May; 98():103720. PubMed ID: 32171982
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design, synthesis and molecular modeling study of certain VEGFR-2 inhibitors based on thienopyrimidne scaffold as cancer targeting agents.
    Ghith A; Youssef KM; Ismail NSM; Abouzid KAM
    Bioorg Chem; 2019 Mar; 83():111-128. PubMed ID: 30343204
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans.
    Thorarensen A; Dowty ME; Banker ME; Juba B; Jussif J; Lin T; Vincent F; Czerwinski RM; Casimiro-Garcia A; Unwalla R; Trujillo JI; Liang S; Balbo P; Che Y; Gilbert AM; Brown MF; Hayward M; Montgomery J; Leung L; Yang X; Soucy S; Hegen M; Coe J; Langille J; Vajdos F; Chrencik J; Telliez JB
    J Med Chem; 2017 Mar; 60(5):1971-1993. PubMed ID: 28139931
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, synthesis and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers.
    Elmetwally SA; Saied KF; Eissa IH; Elkaeed EB
    Bioorg Chem; 2019 Jul; 88():102944. PubMed ID: 31051400
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design, synthesis and biological evaluation of novel dithiocarbamate-substituted diphenylaminopyrimidine derivatives as BTK inhibitors.
    Zhai Z; Li R; Bai X; Ning X; Lin Z; Zhao X; Jin Y; Yin Y
    Bioorg Med Chem; 2019 Sep; 27(18):4124-4142. PubMed ID: 31395509
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design, synthesis, and pharmacological evaluation of 4- or 6-phenyl-pyrimidine derivatives as novel and selective Janus kinase 3 inhibitors.
    Shu L; Chen C; Huan X; Huang H; Wang M; Zhang J; Yan Y; Liu J; Zhang T; Zhang D
    Eur J Med Chem; 2020 Apr; 191():112148. PubMed ID: 32097841
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design and synthesis of sulfonamide-substituted diphenylpyrimidines (SFA-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B-cell lymphoblastic leukemia.
    Liu H; Qu M; Xu L; Han X; Wang C; Shu X; Yao J; Liu K; Peng J; Li Y; Ma X
    Eur J Med Chem; 2017 Jul; 135():60-69. PubMed ID: 28432946
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, synthesis, and SAR study of highly potent, selective, irreversible covalent JAK3 inhibitors.
    He L; Shao M; Wang T; Lan T; Zhang C; Chen L
    Mol Divers; 2018 May; 22(2):343-358. PubMed ID: 29411195
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies.
    Wang Y; Zhang LL; Champlin RE; Wang ML
    Clin Pharmacol Ther; 2015 May; 97(5):455-68. PubMed ID: 25669675
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis of Novel Thieno[2,3-d]pyrimidine Derivatives and Evaluation of Their Cytotoxicity and EGFR Inhibitory Activity.
    Adly ME; Gedawy EM; El-Malah AA; El-Telbany FA
    Anticancer Agents Med Chem; 2018; 18(5):747-756. PubMed ID: 29366427
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of potent and highly selective covalent inhibitors of Bruton's tyrosine kinase bearing triazine scaffold.
    Teng Y; Lu X; Xiao M; Li Z; Zou Y; Ren S; Cheng Y; Luo G; Xiang H
    Eur J Med Chem; 2020 Aug; 199():112339. PubMed ID: 32402933
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting JAK3 tyrosine kinase-linked signal transduction pathways with rationally-designed inhibitors.
    Uckun FM; Vassilev A; Dibirdik I; Tibbles H
    Anticancer Agents Med Chem; 2007 Nov; 7(6):612-23. PubMed ID: 18045056
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.